KNOXVILLE, Tenn. -- (BUSINESS WIRE) -- Provectus Biopharmaceuticals, Inc. (PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has appointed Jacob M. Plotsker to its strategic advisory board.
Mr. Plotsker, age 46, is currently Director of IUS Strategy and Lifecycle Management at Bayer Healthcare. Jacob started his career as a staff accountant at Deloitte & Touche. He started his career in the pharmaceutical industry in 1990 when he joined Pfizer, where over the next 16 years he held roles of increasing responsibility in the Finance and Marketing functions. He subsequently moved to Organon BioSciences/Schering Plough as Senior Director of US and Global Marketing. From 2009 to 2012, he worked for Teva Pharmaceuticals as Head of Marketing and Senior Director, Commercial Operations in the branded Women’s Health Division.
Mr. Plotsker currently serves on the board of directors of Emisphere Technologies, a publicly traded drug delivery technology company. From 2008 to 2014, he served on the board of directors of Sharsheret, a national 501(c)(3) not-for-profit organization providing support and resources to young women living with breast cancer. He served as President of Sharsheret from 2009-2012.
He holds a BA from Queens College of the City University of New York, an MBA from the Stern School of Business at New York University, and completed the Executive Program in General Management at the University of Chicago’s Booth School of Business.
Dr. Craig Dees, PhD, CEO of Provectus said, "We are very happy that Jacob is joining the Provectus Strategic Advisory Board. He is a seasoned executive with extensive experience in US and international marketing, product launches and commercial operations in the pharmaceutical industry. Provectus will benefit greatly from all of these talents and abilities as we work to bring PV-10 and other preparations to the marketplace.”
Mr. Plotsker said, “I am excited at becoming a member of the Provectus Strategic Advisory Board. The Company is at a very important juncture in its development. PV-10’s pending application for breakthrough therapy designation is an important milestone for the product and the Company. As the Company continues to advance the development of PV-10, the preparation for commercialization will take on an increasingly important role. I look forward to leveraging my experience to benefit patients in need of new therapies and contributing to Provectus’ future success.”
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.